PH-PS treatment in 5×FAD Alzheimer's disease mice

Validation Score: 0.900 Price: $0.50 Alzheimer's disease 5×FAD transgenic mice Status: proposed

What This Experiment Tests

Validation experiment designed to validate causal mechanisms targeting N/A in 5×FAD transgenic mice. Primary outcome: learning and spatial memory deficits

Description

This comprehensive study investigated the neuroprotective effects of Pseudostellaria heterophylla polysaccharide (PH-PS) in 5×FAD transgenic mice, a well-established animal model of Alzheimer's disease. The experiment examined multiple endpoints including cognitive function, neuropathology, neuroinflammation, and gut microbiome changes. Researchers characterized the PH-PS extract (molecular weight 8.771 kDa, composed of 57.78% glucose, 41.52% galactose, and 0.70% arabinose) and administered it to 5×FAD mice. The study employed behavioral testing to assess learning and spatial memory, histological analysis to evaluate amyloid β plaque burden and glial activation, 16S rRNA sequencing to analyze gut microbiome composition, and molecular analyses to examine inflammatory markers and amyloid-degrading enzymes. The research demonstrated that PH-PS treatment improved cognitive deficits, reduced amyloid pathology, modulated microglial and astrocytic polarization from pro-inflammatory (M1/A1) to anti-inflammatory (M2/A2) phenotypes, restored intestinal barrier function, and promoted beneficial gut bacteria while suppressing harmful inflammatory bacteria.

TARGET GENE
N/A
MODEL SYSTEM
5×FAD transgenic mice
ESTIMATED COST
$0
TIMELINE
0 months
PATHWAY
amyloid beta clearance, neuroinflammation, gut-brain axis
SOURCE
extracted_from_pmid_38750854
PRIMARY OUTCOME
learning and spatial memory deficits

Scoring Dimensions

Info Gain 0.00 (25%) Feasibility 0.00 (20%) Hyp Coverage 0.00 (20%) Cost Effect. 0.00 (15%) Novelty 0.00 (10%) Ethical Safety 0.00 (10%) 0.900 composite

📖 Wiki Pages

ResearchersindexAgitation in Alzheimer's DiseasediseaseAlzheimer's DiseasediseaseAlzheimer's DiseasediseaseAlzheimer's Disease Genetic VariantsdiseaseAlzheimer's Disease vs Parkinson's Disease ComparidiseaseAPP Mutations in Alzheimer's DiseasediseaseDLB, Parkinson's Disease, and Alzheimer's Disease:diseaseEarly-Onset Alzheimer's Disease (EOAD)diseaseInvestment Landscape: Alzheimer's DiseasediseasePreclinical Alzheimer's DiseasediseaseProdromal Alzheimer's DiseasediseasePSEN1 Mutations in Alzheimer's DiseasediseasePSEN2 Mutations in Alzheimer's DiseasediseaseSporadic vs Familial Alzheimer's Disease: Comprehedisease

Protocol

  • Establish 5×FAD transgenic mice cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for the nominated disease mechanism, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure learning and spatial memory deficits together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5.
  • ...

    Expected Outcomes

  • The intervention targeting the nominated disease mechanism shifts learning and spatial memory deficits in the predicted direction relative to the matched control arm.
  • Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects.
  • The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.
  • Success Criteria

    Ameliorated memory deficits, reduced amyloid β build-up, suppressed reactive glia and astrocytes, improved gut microbiota composition

    Related Hypotheses (5)

    Microglial TREM2 downregulation impairs damage-associated response in late-stage Alzheimer's disease0.626
    APOE4-Targeted Ultrasonic Lipidation Enhancement for Gamma Oscillation Restoration in Alzheimer's Di0.625
    TREM2-mediated microglial tau clearance enhancement0.618
    LRP1-Dependent Tau Uptake Disruption0.600
    Extracellular Vesicle Biogenesis Modulation0.582

    Debate History (0)

    No debates yet

    Experiment Results (0)

    No results recorded yet. Use POST /api/experiments/{id}/results to record a result.